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Abstract
Background: The United States Centers for Disease Control and Prevention estimates that approximately 60,000 US youth are
living with HIV. US youth living with HIV (YLWH) have poorer outcomes compared with adults, including lower rates of
diagnosis, engagement, retention, and virologic suppression. With Adolescent Medicine Trials Network for HIV/AIDS Interventions
(ATN) support, new trials of youth-centered interventions to improve retention in care and medication adherence among YLWH
are underway.
Objective: This study aimed to use a computer simulation model, the Cost-Effectiveness of Preventing AIDS Complications
(CEPAC)-Adolescent Model, to evaluate selected ongoing and forthcoming ATN interventions to improve viral load suppression
among YLWH and to define the benchmarks for uptake, effectiveness, durability of effect, and cost that will make these
interventions clinically beneficial and cost-effective.
Methods: This protocol, ATN 161, establishes the ATN Modeling Core. The Modeling Core leverages extensive data—already
collected by successfully completed National Institutes of Health–supported studies—to develop novel approaches for modeling
critical components of HIV disease and care in YLWH. As new data emerge from ongoing ATN trials during the award period
about the effectiveness of novel interventions, the CEPAC-Adolescent simulation model will serve as a flexible tool to project
their long-term clinical impact and cost-effectiveness. The Modeling Core will derive model input parameters and create a model
structure that reflects key aspects of HIV acquisition, progression, and treatment in YLWH. The ATN Modeling Core Steering
Committee, with guidance from ATN leadership and scientific experts, will select and prioritize specific model-based analyses
as well as provide feedback on derivation of model input parameters and model assumptions. Project-specific teams will help
frame research questions for model-based analyses as well as provide feedback regarding project-specific inputs, results, sensitivity
analyses, and policy conclusions.
Results: This project was funded as of September 2017.
Conclusions: The ATN Modeling Core will provide critical information to guide the scale-up of ATN interventions and the
translation of ATN data into policy recommendations for YLWH in the United States.
(JMIR Res Protoc 2019;8(4):e9898)  doi: 10.2196/resprot.9898
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Introduction outcomes and cost-effectiveness, computer-based health policy
models can add substantial value to clinical trials and
observational studies [4]. Projecting such long-term estimates
is particularly important for studies among YLWH, for whom
the health effects of poor virologic control may not manifest
for years or decades [5]. Models can also combine data from
multiple sources and compare a wide range of possible
interventions, leveraging the extensive data collected within
ATN and other studies into timely guideline and policy
recommendations [6]. The Cost-effectiveness of Preventing
AIDS Complications (CEPAC)-computer simulation models
[7] of HIV infection in infants, children, and adults have been
used to inform health policy related to HIV prevention [8,9],
testing [10-12], and care [13-18], both in the United States and
internationally. CEPAC model-based work has been cited in
national HIV care guidelines for the United States, Brazil, Chile,
Mexico, France, and Colombia, among others, as well as in the
World Health Organization (WHO) guidelines [19-23]. For
example, a CEPAC-Pediatrics model-based analysis projected
that use of lopinavir/ritonavir in children younger than 3 years
as first-line antiretroviral therapy (ART) led to longer
life-expectancy and was cost-saving compared with first-line
use of nevirapine; this analysis helped inform the WHO’s
recommendation in 2013 of a lopinavir/ritonavir-based regimen
for first-line ART in that age group [16,24]. To date, few HIV
modeling or cost-effectiveness studies have been conducted
among youth; most have focused on HIV screening and
prevention [25-32]. Previous work has not incorporated age-
and time-varying changes in adolescent and young adult
health-related behavior among YLWH.
Background
Approximately 60,000 youth are living with HIV in the United 
States. Youth living with HIV (YLWH) have poorer outcomes 
than adults living with HIV, including lower rates of diagnosis, 
engagement, retention, and virologic suppression [1,2]. 
Established in 2001 by the Maternal and Pediatric Infectious 
Disease Branch of the Eunice Kennedy Shriver National 
Institutes of Child Health and Development, the Adolescent 
Medicine Trials Network for HIV/AIDS Interventions (ATN) 
has conducted rigorous evaluations of interventions to improve 
medication adherence, retention in care, and viral load (VL) 
suppression among YLWH [3]. ATN is the only national clinical 
research network that specifically studies adolescents aged 12 
to 24 years living with HIV and at risk for acquiring HIV. ATN 
collaborations have included the United States Centers for 
Disease Control and Prevention; the Health Resources and 
Services Administration; the AIDS Clinical Trials Group; the 
HIV Vaccine Trials Network; the HIV Prevention Trials 
Network; the International Maternal, Pediatric, and Adolescent 
AIDS Clinical Trial (IMPAACT) Network; and the Microbicide 
Trials Network. This ATN began with new National Institutes 
of Health (NIH) support in 2016 to fund youth-focused projects 
that aim to reduce risk factors for adolescents at risk of acquiring 
HIV and to promote behaviors related to adherence and 
engagement with care for those living with HIV. ATN currently 
supports 22 protocols [3].
By projecting outcomes beyond the time horizon of traditional 
studies and thereby permitting estimates of long-term clinical
Table 1. National Institutes of Health–supported studies from the Adolescent Medicine Trials Network for HIV/AIDS Interventions and the International
Maternal, Pediatric, and Adolescent AIDS Clinical Trials Network included in the proposed analysis.
PopulationdN (13-24)cAge at enrollmentYearsTitleStudy; timea,b
NPHIVYg130 (all)18-24 years2007-2010T-cells in ARTf deintensificationATNe 061 [33-36]; 2.9 years
NPHIVY and
PHIVYh
2196 (all)12-24 years2011-2012Health status and behavioral risk factorsATN 106/086 [37-40]; 1 year
NPHIVY922 (all)13-24 years2015-2017Treatment at ATN sitesATN 125 [41,42]; 1.5 years
PHIVY294 (199)6-17 years2005-2006Psychiatric conditions in PHIVYPi1055 [41,43,44]; 1.8 years
PHIVY126 (71)1 month to 19 years2007-2013RALj safety, PKk, effectivenessP1066 [45-48]; 1 year
NPHIVY and
PHIVY
1236 (all)0-24 years2009-2014Long-term outcomesP1074 [49-51]; 5.3 years
PHIVY160 (23)1 month to 18 years2011-2018Dolutegravir-based ARTP1093 [52,53]; 2 years
aMean or median follow-up time.
bMinimum key data for all studies: viral loads, cluster of differentiation 4 (CD4) cell count, ART regimens, opportunistic infections, sexually transmitted
infections, pregnancy, and other clinical diagnoses.
cTotal N (n aged 13-24 years): 4904 (4777).
dPopulation: primarily NPHIVY or PHIVY.
eATN: Adolescent Medicine Trials Network for HIV/AIDS Interventions.
fART: antiretroviral therapy.
gNPHIVY: nonperinatally HIV-infected youth.





This protocol will leverage existing data from successfully
completed NIH-supported studies (Table 1) to inform the
development of novel approaches for modeling critical
components of HIV disease and care in YLWH. As ATN
investigators study new interventions to improve VL suppression
among YLWH, the CEPAC-Adolescent computer simulation
model will be developed to define the benchmarks for uptake,
effectiveness, durability of effect, and cost that will make these
interventions clinically beneficial and cost-effective. In addition,
as new data emerge from ongoing ATN trials about the
effectiveness of these interventions, the computer simulation
model will serve as a flexible tool to project the long-term
clinical impact and cost-effectiveness of these interventions.
This project will, therefore, provide critical information to guide
the scale-up of ATN interventions and the translation of ATN
data into policy recommendations for YLWH in the United
States.
Methods
participant recruitment and enrollment capacity. These research
program projects are as follows:
• Comprehensive Adolescent Research and Engagement
Studies [54], a comprehensive community-based project
that aims to optimize the HIV prevention and treatment
continuum for at-risk and acutely infected youth as well as
youth with established HIV infection.
• iTech [55], a research program that aims to impact the HIV
epidemic by conducting innovative, interdisciplinary
research using technology-based interventions across the
HIV prevention and care continuum for adolescents and
young adults.
• Scale it Up [56], a research program that aims to assess and
enhance the real-world effectiveness, implementation, and
scalability of theoretically based and developmentally
tailored interventions focused on improving HIV treatment
and prevention self-management for youth.
Each research program project (U19) supports several individual
protocols [54-56]. The ATN Coordinating Center (U24) is
located at the University of North Carolina at Chapel Hill. The
Coordinating Center provides support, coordination, and
operational infrastructure to ATN. The Coordinating Center
also supports several stand-alone protocols such as “A
Triggered, Escalating, Real-Time Adherence Intervention,”
which uses electronic-dose monitoring to inform an adherence
intervention for youth without virologic suppression. The
Coordinating Center also supports the Modeling Core.
Adolescent Medicine Trials Network for HIV/AIDS 
Interventions Structure and Establishment of the 
Modeling Core
The ATN structure consists of 3 ATN research program projects 
(U19s) and a Coordinating Center (U24; Figure 1). Each of the 
3 ATN research program projects (U19) has a well-defined 
research focus supported by core infrastructures as well as
assembled for each analysis. Each project team will include
Modeling Core investigators and the protocol chair or a
representative from the trial being analyzed. Project team
members have expertise in multiple relevant areas including
epidemiology, health services research, economics, intervention
science, implementation science, behavioral science, clinical
trials development, and the clinical care of YLWH. Project
teams will help develop the research question, identify any
additional structural simulation model modifications, provide
input on needed data parameters (eg, help identify potential
issues of population mismatch for parameters derived from
different sources), and review preliminary model results (eg,
for face validity and identifying key sensitivity analyses).
Abstracts, presentations, and manuscripts presenting model
results will be reviewed in accordance with the ATN
publications policy.
Figure 1. Organizational structure of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN).
The Modeling Core has established a Modeling Core Steering 
Committee that will meet regularly and include Modeling Core 
investigators, at least 1 principal investigator or liaison from 
each of the 3 ATN research program projects (U19s) and the 
ATN Coordinating Center, protocol chairs or representatives 
from stand-alone trials for which modeling is planned, and 
additional interested ATN investigators.
ATN investigators in the Modeling Core Steering Committee 
will provide feedback on the derivation of data inputs, design 
of new model structure within the CEPAC-Adolescent model, 
and selection of policy analyses to perform. Once specific ATN 
studies are identified as potential candidates for modeling 
analyses, the Modeling Core investigators will work with 
relevant protocol teams to ensure that data likely to be useful 
for later modeling are collected prospectively in each study.
After the Modeling Core Steering Committee has determined 
which policy analyses will be performed, project teams will be
Textbox 1. Categories of key outcomes (specific events within each listed category will also be analyzed separately).
Categories of key outcomes:
• Centers for Disease Control and Prevention (CDC) HIV clinical diagnoses (CDC-A, B, and C)
• Severe or life-threatening, non-HIV–related diagnoses (eg, pneumococcal events)
• Chronic non-HIV-related diagnoses (eg, cardiac and renal disease and malignancy)
• Medication toxicity (division of AIDS ≥Grade 2)
• Psychiatric events
• Sexually transmitted infections
• Pregnancy or pregnancy outcomes
• Death
outcome to be modeled, secondary outcome measures to be
included, and the types of economic estimates to be derived
from the model.
Design for Objective 1
The design for Objective 1 was to determine rates of key clinical
events for YLWH engaged in care stratified by age, CD4 cell
count, and ARV and VL status in completed and ongoing
NIH-supported studies.
Incidence rates of key clinical events (Textbox 1) will be
described based on current age, sex, current CD4, current ARV
use, and VL as well as mode of HIV acquisition (perinatally
HIV-infected youth [PHIVY] or nonperinatally HIV-infected
youth [NPHIVY]) [58]. These data will permit assigning risks
of clinical events to simulated patients in the simulation model
developed in Objective 2.
Population and Data Sources
Formal requests were approved to analyze data from 4800
YLWH in completed NIH-supported studies after appropriate
data use agreement and network approvals were secured (Table
1). These studies include observational studies, nonrandomized
interventions, and a randomized trial. All include youth aged
13 to 24 years at study entry. The primary focus of each study
ranged widely, from determining the safety and efficacy of ARV
medications to evaluating clinical, immunological, and
psychiatric outcomes. All included a minimum set of key
outcomes needed for this analysis, and all clinical events were
recorded using comparable diagnostic codes. Protocols and data
collection forms from all studies will be reviewed to understand
how data can be harmonized among studies, as has been done
in previous analyses [58]. Resource use input parameters will
be derived from adolescent intervention or trial-specific data
where available, as in previous work [29,59]. New data
emerging from ongoing studies will be integrated into the model.
Data Management
Data analysis concept sheets and data use agreements have been
approved for these analyses by individual networks as well as
through the Eunice Kennedy Shriver National Institute of Child
Health and Development Data and Specimen Hub repository
[60]. Data will be cleaned (when applicable), harmonized, and
safely stored at the Center for Biostatistics in AIDS Research
at the Harvard TH Chan School of Public Health, which is
Scientific Objectives’ Overview
Objective 1
Objective 1 was to determine rates of key clinical events for 
YLWH engaged in care stratified by age, CD4 cell count, and 
antiretroviral (ARV) and VL status in completed and ongoing 
NIH-supported studies. Using ClinicalTrials.gov [57], studies 
were reviewed that included YLWH aged 13 to 24 years at the 
US sites, and collected data related to CD4 cell count, VL, and 
ART regimens as well as clinical event data during the era of 
modern ART. Selected studies were conducted within the 2 
largest NIH-sponsored national networks supporting clinical 
trials and observational studies in youth affected by HIV—the 
ATN and the IMPAACT Network. Incidence rates of 
opportunistic infections; HIV and non-HIV events (Textbox 1); 
and mortality based on age, sex, patterns of CD4 count and VL, 
and ARV use among YLWH will be evaluated in completed 
and ongoing NIH-sponsored studies (Table 1) in accordance 
with individual data use agreements.
Objective 2
Objective 2 was to develop the CEPAC-Adolescent model—a 
simulation model to reflect unique characteristics of YLWH.
The CEPAC-Adolescent simulation model will be developed 
to reflect the unique characteristics of YLWH. The foundational 
inputs of the expanded model will be populated with estimates 
from completed and ongoing NIH-supported studies (Table 1) 
derived in Objective 1 as well as other published sources. As 
new data emerge from the ATN or other sources related to 
clinical events, resource utilization, and specific interventions, 
model inputs will be updated.
Objective 3
Objective 3 was to use the simulation model to project the 
clinical impact, cost, and cost-effectiveness of selected 
interventions evaluated in ATN.
The Modeling Core Steering Committee will work with the 
ATN Executive Committee and the ATN External Scientific 
Panel to prioritize ATN studies for model-based analyses, based 
on data availability and the most relevant questions in health 
care policy for YLWH each year. The Modeling Core Steering 
Committee functions will include activities such as providing 
feedback on the costing perspectives to be used, the primary
identify groups of participants following similar trajectories, in
a secondary analysis, we will assess associations between
baseline characteristics of study participants and membership
in particular trajectory groups. In the CEPAC-Adolescent model,
these attributes will be used to account for heterogeneity in care
engagement.
Design for Objective 2
The design for Objective 2 was to develop a simulation model
to reflect the unique characteristics of YLWH.
Current Model Structure
The CEPAC-Adult and -Pediatric models are Monte Carlo,
state-transition models of HIV disease and treatment
[7,8,17,18,29,65]. The models simulate people living with HIV
with user-specified characteristics including age, CD4 cell count,
VL, and treatment history, from model entry until death. In the
absence of effective ART, CD4 cell counts decline monthly;
with VL suppression, CD4 cell counts rise at user-specified
rates. In each month, modeled patients face risks of key clinical
events, such as opportunistic infections, other illnesses, and
mortality, determined by current age and current CD4 cell count.
Patients can also initiate or continue ARVs, with subsequent
VL suppression or virologic failure, and can be lost to follow-up.
Onward transmission risk is determined by pooled cohort VL
levels using rates derived from published estimates (eg,
2.06/100PY transmission with HIV RNA of 3000-10,000
copies/mL) from adolescents, where available [66,67].
Patients are simulated within the model one at a time; the model
tracks their clinical course, from time of entry into the model
until death. Upon a patient’s death, the model records summary
statistics, and a new patient then enters the model. This
continues until the last patient in a cohort dies and exits the
model, at which time the model tallies clinical events, durations
spent in each health state, monthly life and quality-adjusted life
expectancies, and costs. State transitions are stochastic and
determined by the Mersenne Twister random number generator
algorithm [68] that was adapted for use in C++, the
programming language of CEPAC. When finished running,
model output can be extracted and analyzed by the user, as
shown in Figure 2, which traces a simulated patient’s CD4 cell
count and HIV RNA over the course of several important
clinical events.
Adolescent-specific patterns of medication adherence and care
engagement will be simulated based on work in Objective 1.
Currently, in the CEPAC models, clinical event risk, retention
in care, and adherence vary between individual people, but do
not vary over time or with changes in development or life events.
The new model structure will be developed to reflect age- and
time-varying adolescent- and young adult-specific aspects of
HIV disease progression and care for YLWH based on these
patterns. The model structure will account for
heterogeneity—the specific additions to the model structure
will be informed by the data generated through activities
conducted as a part of Objective 1. Additional details of the
existing CEPAC models, including flowcharts, a user guide,
and sample patient traces can be found on the CEPAC website
[7].
compliant with federal regulations governing information 
security.
Outcomes
Clinical events that impact short- and long-term (lifetime) 
outcomes and health care costs, such as the occurrence of 
specific opportunistic infections, non-AIDS-defining illnesses, 
sexually transmitted infections, pregnancy, and psychiatric 
events, within the categories listed in Textbox 1 will be 
analyzed.
Statistical Analysis
Incidence rates of each outcome will be estimated, stratified by 
mode of HIV acquisition and the combination of time-varying 
age (7-12, 13-17, 18-24, and 25-30 years), CD4 cell count (<200,
200-499, and ≥500/µL), and VL and ARV status, as in previous 
work [58]. The VL or ARV status will be categorized as follows:
(1) suppressive ARVs—VL less than 400 copies/mL and any 
prescribed ARVs, (2) nonsuppressive ARVs—VL 400 
copies/mL or more and prescribed ARVs expected to be 
suppressive, and (3) no ARVs—VL 400 copies/mL or more 
and no prescribed ARVs [58]. Linear interpolation between 
CD4 cell counts and log10-transformed VL will be used to 
estimate dates when strata thresholds are crossed. These 
estimated dates will allow us to determine baseline strata and 
calculate total person-time contributed to each stratum.
As in previous work, trends in incidence rates of outcomes 
across ordinal age, CD4 cell count, and VL/ARV categories, 
stratified by mode of HIV acquisition, will be assessed using 
Poisson regression models, accounting for within-subject 
correlation with robust SEs [61]. The hypothesis that higher 
rates of clinical events will be associated with person-time spent 
with lower CD4 counts, older age, and at higher VL will be 
examined [58]. VL of 400 copies/mL or more was selected 
based on historic lower levels of detection for assays used during 
the study period [58].
We will also advance approaches to describe and predict the 
trajectories of CD4, VL, and care engagement over time. Locally 
weighted smoothing plots will be used to obtain a graphical 
summary of CD4 and VL trajectories over time by mode of 
HIV acquisition and baseline age [62]. On the basis of visual 
inspection, linear regression or piecewise linear regression 
models will be fitted to obtain slope parameters for CD4 and 
VL over follow-up time among subjects with at least 2 available 
measures. Baseline covariates such as mode of HIV acquisition, 
age, CD4 count, VL, and ART regimen will be added to these 
regression models to assess association with observed CD4 and 
VL trajectories. To determine whether there are any important 
differences between subjects with longitudinal CD4 and VL 
data and those missing such data, baseline characteristics will 
be compared between these 2 populations.
If there are sufficient numbers of YLWH who miss visits or are 
lost to follow-up, these will also be used to identify patterns of 
care followed by distinct subgroups such as those who are in 
care, those who are care interrupters, and those who are not in 
care. Latent trajectory groups will be identified from the study 
data with group-based trajectory modeling [63,64]. After we
Figure 2. Sample simulated patient trace. CD4 cell count (cells/mm3) is presented on the vertical left-most axis and in the blue line. HIV RNA
(copies/mL) is presented on the vertical right-most axis and in the red line. The horizontal axis shows years from model start. The dashed lines mark
key clinical events for a simulated patient: initiating ART but failing to suppress HIV RNA and without improvement in CD4 cell count; receiving
adherence counseling leading to HIV RNA suppression and improvement in CD4 cell count; becoming lost to follow up with subsequent rise in HIV
RNA and decline in CD4 cell count; developing an opportunistic infection resulting in returning to care and reinitiating ART with subsequent HIV
RNA suppression and improvement in CD4 cell count; and eventual death from non-AIDS-related causes. ART: antiretroviral therapy.
next be calibrated to data from the literature and the studies in
Objectives 1 and 2 to reflect current populations of YLWH and
treatment strategies. One-way, multiway, and probabilistic
sensitivity analyses will be conducted, following international
guidelines to address uncertainty in data inputs for the model
[70,71]. This involves varying single and multiple parameters
over wide ranges and reassessing all clinical results and
cost-effectiveness outcomes. Sensitivity analyses can inform
the potential impact of strategies in scenarios that more closely
resemble programmatic rather than trial settings.
Design for Objective 3
The design for Objective 3 was to use the computer simulation
model to project the clinical impact, costs, and cost-effectiveness
of interventions evaluated in ATN.
Clinical data not specific to ATN interventions will be from
Objective 1, reflecting key components of disease progression
and treatment for youth with and without VL suppression.
Intervention-specific data will be derived from the ATN studies
selected for model-based analyses; for ATN interventions,
effectiveness, duration of effect, and intervention cost will be
parameterized based on data from each modeled ATN trial.
Model outcomes will include short-term survival and costs
(calibrated to trial results) as well as projected long-term survival
and costs, including life expectancy and lifetime per-person
costs, and transmissions averted. To compare interventions,
incremental cost-effectiveness ratios (difference in lifetime costs
divided by the difference in life expectancy, in dollars per
year-of-life saved) will be calculated and compared with
Translating Objective 1 Data Into Model Inputs
Incidence rates of clinical events (Textbox 1, Objective 1) will 
be converted into monthly event probabilities. During each 
patient-month for which a specific set of characteristics apply 
(age, CD4, and ARV/VL category), these data will be used to 
assign a modeled risk of each key clinical event over the next 
30-day period.
Resource utilization and cost data related to HIV care, ART, 
and the occurrence of acute events will be derived from 
adolescent-specific literature when available and otherwise will 
be derived from adult literature and varied in sensitivity 
analyses, as in previous work [29]. When specific interventions 
and studies are identified as candidates for model-based 
analyses, the Modeling Core will work with study teams to 
collect the data necessary for future model-based analyses in 
real time (eg, time and motion studies, activity logs, and costs 
of personnel and supplies).
Model Validation and Approach to Uncertainty
The model will be internally validated, assessing the accuracy 
of the model structure by comparing model output (opportunistic 
infections, viral suppression probability, and survival) with the 
empiric data in the studies from which model input parameters 
were derived [69]. As the model projects outcomes over lifetime 
horizons, the longer-term model results cannot be compared 
with empiric data; however, as ATN-studied interventions 
become more widely implemented over time, past model results 
will be compared with newly available data. The model will
1. Work with trial teams to develop study protocols, ensuring
collection of data needed for modeling.
2. Conduct pretrial modeling analyses to inform study design
and establish benchmarks for interpretation of trial results.
For example, to inform study design, detailed simulations
of disease progression and clinical events in youth can
provide additional input into sample size calculations, and
model-based projections can inform study protocol elements
such as frequency of study visits and maximal permitted
turnaround time for return of diagnostic test results. To
establish benchmarks for interpretation, model-based
projections under a range of assumptions about efficacy
and cost can be used to identify critical thresholds for key
study outcomes: how effective and durable would an
intervention need to be for that intervention to add benefit
to current practice? For any given efficacy and effect
duration, at what cost and level of uptake would the
intervention be cost-effective?
3. Conduct modeling analyses alongside trials to evaluate the
potential clinical impact and cost-effectiveness of trial
interventions when implemented at scale for YLWH in the
United States.
4. Identify key parameters that may influence policy
conclusions such as the cost of electronic dose monitoring
bottles or duration of improved adherence after incentives.
If data on these key parameters are lacking, this limitation
can help identify new research priorities. The Modeling
Core will work with ATN leadership to ensure this feedback
informs the ATN strategic planning.
Role of the Funding Sources
The content of this manuscript is solely the responsibility of the
authors and does not necessarily represent the official views of
the National Institutes of Health.
Results
This project was funded as of September 2017.
Discussion
The planned data analyses and model development in Objectives
1 and 2 will position the ATN Modeling Core to evaluate a wide
range of new ATN studies and other emerging data. Future work
may include new therapies that are likely to be studied in the
near future among YLWH, for example, long-acting ART [78].
The Modeling Core also collaborates with the ATN Data
Harmonization Working Group to standardize the collection of
resource utilization and cost data across all active ATN studies
[79].
Strengths and Limitations
This protocol has several limitations inherent to model-based
analyses. First, many models necessarily use short-term data to
project across longer-term horizons. This extrapolation requires
assumptions about whether and how trial-derived clinical risks
and costs will change over time. However, when these
assumptions are clearly described, examined rigorously in
sensitivity analyses, and interpreted appropriately, this ability
of models to leverage short-term data into longer-term policy
recommendations is one of the key strengths of model-based
approaches [4,69]. Second, research participants in Objective
1 studies may not be representative of the larger population of
YLWH in the United States. However, these studies remain
among the best sources of data for YLWH in the United States.
Study-derived risks will be varied widely in model-based
sensitivity analyses to examine the potential impact of variations
in these results.
Conclusions
In summary, a Modeling Core has been established within ATN
161. A computer simulation model reflecting disease
progression, care and treatment outcomes, and HIV transmission
among adolescents and young adults will be developed. YLWH
are a growing and vulnerable population in the United States,
in whom lack of VL suppression contributes to poor clinical
outcomes for individual patients, increases health care costs,
and drives the ongoing HIV epidemic. Existing data from
completed and ongoing NIH-supported studies will be leveraged
to develop the adolescent-specific model. The Modeling Core
Steering Committee will work closely with ATN leadership and
investigators to design and conduct model-based analyses,
addressing critical questions about HIV care among YLWH
that cannot be fully answered by trials and cohort studies. The
Modeling Core will also build a foundation to inform the design
of new studies of interventions across ATN and to evaluate the
clinical impact and cost-effectiveness of those interventions,
directly translating the work of ATN into critical policy
recommendations for YLWH in the United States.
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commonly used thresholds for the United States [72]. 
Adolescents comprise only a small fraction of participants in 
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